{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T15:00:26Z","timestamp":1788102026506,"version":"build-2803163510"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,1,22]],"date-time":"2017-01-22T00:00:00Z","timestamp":1485043200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Theravance Biopharma Antibiotics, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s10096-016-2865-8","type":"journal-article","created":{"date-parts":[[2017,1,22]],"date-time":"2017-01-22T01:07:13Z","timestamp":1485047233000},"page":"1013-1017","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Update of the activity of telavancin against a global collection of Staphylococcus aureus causing bacteremia, including endocarditis (2011\u20132014)"],"prefix":"10.1007","volume":"36","author":[{"given":"R. E.","family":"Mendes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. S.","family":"Sader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. I.","family":"Smart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Castanheira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. K.","family":"Flamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,22]]},"reference":[{"issue":"3","key":"2865_CR1","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1128\/CMR.00134-14","volume":"28","author":"SY Tong","year":"2015","unstructured":"Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VG Jr (2015) Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev 28(3):603\u2013661. doi:\n10.1128\/CMR.00134-14","journal-title":"Clin Microbiol Rev"},{"issue":"5","key":"2865_CR2","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/j.1469-0691.2012.03903.x","volume":"19","author":"KB Laupland","year":"2013","unstructured":"Laupland KB, Lyytik\u00e4inen O, S\u00f8gaard M, Kennedy KJ, Knudsen JD, Ostergaard C, Galbraith JC, Valiquette L, Jacobsson G, Collignon P, Sch\u00f8nheyder HC; International Bacteremia Surveillance Collaborative (2013) The changing epidemiology of Staphylococcus aureus bloodstream infection: a multinational population-based surveillance study. Clin Microbiol Infect 19(5):465\u2013471. doi:\n10.1111\/j.1469-0691.2012.03903.x","journal-title":"Clin Microbiol Infect"},{"issue":"15","key":"2865_CR3","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1001\/jama.298.15.1763","volume":"298","author":"RM Klevens","year":"2007","unstructured":"Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, Craig AS, Zell ER, Fosheim GE, McDougal LK, Carey RB, Fridkin SK; Active Bacterial Core surveillance (ABCs) MRSA Investigators (2007) Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298(15):1763\u20131771. doi:\n10.1001\/jama.298.15.1763","journal-title":"JAMA"},{"key":"2865_CR4","unstructured":"VIBATIV Package Insert (2016) Theravance"},{"issue":"12 Suppl 1","key":"2865_CR5","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/01.ccm.0000509363.39114.5c","volume":"44","author":"B Friedman","year":"2016","unstructured":"Friedman B, Bressler A, Cleveland K, Lat A, Helgeson M, Sherman C, Castaneda-Ruiz B (2016) 686: telavancin observational use registry: preliminary results for bacteremia and endocarditis. Crit Care Med 44(12 Suppl 1):248. doi:\n10.1097\/01.ccm.0000509363.39114.5c","journal-title":"Crit Care Med"},{"key":"2865_CR6","volume-title":"M07-A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u2014tenth edition","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2015","unstructured":"Clinical and Laboratory Standards Institute (CLSI) (2015) M07-A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u2014tenth edition. CLSI, Wayne"},{"key":"2865_CR7","volume-title":"M100-S25. Performance standards for antimicrobial susceptibility testing; twenty-fifth informational supplement","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2015","unstructured":"Clinical and Laboratory Standards Institute (CLSI) (2015) M100-S25. Performance standards for antimicrobial susceptibility testing; twenty-fifth informational supplement. CLSI, Wayne"},{"key":"2865_CR8","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST) (2016) Breakpoint tables for interpretation of MICs and zone diameters. Version 6.0, January 2016. Available online at: \nhttp:\/\/www.eucast.org\/clinical_breakpoints\/\n\n. Accessed Jan 2016"},{"issue":"6","key":"2865_CR9","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1086\/653068","volume":"31","author":"K Kreisel","year":"2010","unstructured":"Kreisel K, Roghmann MC, Shardell M, Stine OC, Perencevich E, Lesse A, Gordin F, Climo M, Johnson JK (2010) Assessment of the 48-hour rule for identifying community-associated methicillin-resistant Staphylococcus aureus infection complicated by bacteremia. Infect Control Hosp Epidemiol 31(6):657\u2013659. doi:\n10.1086\/653068","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"3","key":"2865_CR10","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1093\/cid\/ciq146","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF; Infectious Diseases Society of America (2011) Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 52(3):e18\u2013e55. doi:\n10.1093\/cid\/ciq146","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2865_CR11","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/cid\/ciu971","volume":"60","author":"GR Corey","year":"2015","unstructured":"Corey GR, Rubinstein E, Stryjewski ME, Bassetti M, Barriere SL (2015) Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus. Clin Infect Dis 60(5):787\u2013796. doi:\n10.1093\/cid\/ciu971","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2865_CR12","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1128\/AAC.04616-14","volume":"59","author":"RE Mendes","year":"2015","unstructured":"Mendes RE, Sader HS, Flamm RK, Farrell DJ, Jones RN (2015) Telavancin in vitro activity against a collection of methicillin-resistant Staphylococcus aureus isolates, including resistant subsets, from the United States. Antimicrob Agents Chemother 59(3):1811\u20131814. doi:\n10.1128\/AAC.04616-14","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"2865_CR13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.diagmicrobio.2014.12.011","volume":"81","author":"RE Mendes","year":"2015","unstructured":"Mendes RE, Farrell DJ, Sader HS, Streit JM, Jones RN (2015) Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method. Diagn Microbiol Infect Dis 81(4):275\u2013279. doi:\n10.1016\/j.diagmicrobio.2014.12.011","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"2","key":"2865_CR14","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1179\/1973947815Y.0000000050","volume":"28","author":"RE Mendes","year":"2016","unstructured":"Mendes RE, Flamm RK, Farrell DJ, Sader HS, Jones RN (2016) Telavancin activity tested against Gram-positive clinical isolates from European, Russian and Israeli hospitals (2011\u20132013) using a revised broth microdilution testing method: redefining the baseline activity of telavancin. J Chemother 28(2):83\u201388. doi:\n10.1179\/1973947815Y.0000000050","journal-title":"J Chemother"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-016-2865-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-016-2865-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-016-2865-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T12:41:41Z","timestamp":1495543301000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-016-2865-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,22]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["2865"],"URL":"https:\/\/doi.org\/10.1007\/s10096-016-2865-8","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,22]]}}}